Merck and Co Inc (MRK) Actualités

Merck to Participate in the TD Cowen 45th Annual Health Care Conference

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Caroline Litchfield, executive vice president and...

The Gross Law Firm Notifies Merck & Co., Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - MRK

The Gross Law Firm Notifies Merck & Co., Inc. Investors of a Class Action Lawsuit and Upcoming Deadline...

Form 4 - Statement of changes in beneficial ownership of securities

Merck & Co., Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before April 14, 2025 to Discuss Your Rights - MRK

Merck & Co., Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before April 14, 2025 to...

Form 144 - Report of proposed sale of securities

WELIREG® (belzutifan) Receives First European Commission Approval for Two Indications

WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union Merck (NYSE: MRK), known as MSD...

Form 13F-HR - Quarterly report filed by institutional managers, Holdings

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Merck Announces Phase 3 waveLINE-010 Trial Initiation Evaluating Zilovertamab Vedotin, an Investigational Antibody-Drug Conjugate, for the Treatment of Patients With Previously Untreated Diffuse Large B-Cell Lymphoma

Expansion of the waveLINE clinical development program demonstrates company’s progress in advancing research in hematologic malignancies Merck...

Form 8-K - Current report